Bookmark and Share
BioAssay: AID 2503

SAR analysis of Muramyl dipeptide (MDP) induced IL-8 secretion in MCF-7/NOD2 cells - Set 2

The modulation of immune response activity is one of the major goals in the development of novel therapeutics for auto-immune and inflammatory diseases. The innate system resides at the intersection of the pathways of microbial recognition, inflammation, and cell death, thereby offering various therapeutic targets. In this context, NOD1 and NOD2 are of particular interest, since they recognize distinct structures derived from bacterial peptidoglycans and directly activate NF-kB, a central regulator of immune response, inflammation, and apoptosis. ..more
_
   
 Tested Compounds
 Tested Compounds
All(24)
 
 
Active(4)
 
 
Inactive(20)
 
 
 Tested Substances
 Tested Substances
All(25)
 
 
Active(5)
 
 
Inactive(20)
 
 
AID: 2503
Data Source: Burnham Center for Chemical Genomics (BCCG-A316-NOD2-IL-8-MDP-DryPowder-Assay-2)
BioAssay Type: Confirmatory, Concentration-Response Relationship Observed
Depositor Category: NIH Molecular Libraries Probe Production Network
BioAssay Version:
Deposit Date: 2010-03-09
Hold-until Date: 2010-09-02
Modify Date: 2011-01-13

Data Table ( Complete ):           View Active Data    View All Data
Target
BioActive Compounds: 4
Related Experiments
Show more
AIDNameTypeProbeComment
1566uHTS luminescence assay for the identification of compounds that inhibit NOD2Confirmatory depositor-specified cross reference
1575Summary assay for the identification of compounds that inhibit NOD1Summary2 depositor-specified cross reference: Summary AID.
1578uHTS luminescence assay for the identification of compounds that inhibit NOD1Confirmatory depositor-specified cross reference
1579Summary assay for the identification of compounds that inhibit NOD2Summary depositor-specified cross reference: Summary AID.
1848uHTS Fluorescence assay for the identification of cytotoxic compounds among compounds active in NOD2 cell inhibition assayConfirmatory depositor-specified cross reference
1849uHTS Fluorescence assay for the identification of cytotoxic compounds among compounds active in NOD1 cell inhibition assayConfirmatory depositor-specified cross reference
1852HTS assay for identification of inhibitors of TNF-a-specific NF-kB inductionOther depositor-specified cross reference
2001uHTS luminescence assay for the identification of compounds that inhibit NOD2 in MDP treated cellsConfirmatory depositor-specified cross reference
2260SAR analysis of muramyl dipeptide (MDP) induced IL-8 secretion in MCF-7/NOD2 cells.Confirmatory depositor-specified cross reference
2245SAR analysis of tumor necrosis factor alpha (TNF-alpha) induced IL-8 secretion in MCF-7/NOD1 cells.Confirmatory same project related to Summary assay
2250SAR analysis of GM-Tri-DAP induced IL-8 secretion in MCF-7/NOD1 cellsConfirmatory same project related to Summary assay
2255SAR analysis of NF-kB dependent luciferase using Doxorucibin as an inducerConfirmatory same project related to Summary assay
2261SAR analysis of NF-kB dependent luciferase using PMA/Ionomycin as an inducerConfirmatory same project related to Summary assay
2264SAR analysis of NF-kB dependent luciferase using DAP as an inducerConfirmatory same project related to Summary assay
2333SAR analysis of compounds that inhibit NOD1 revisedConfirmatory same project related to Summary assay
2334SAR analysis of compounds that inhibit NOD2 revisedConfirmatory same project related to Summary assay
2335SAR analysis of compounds that are cytotoxic to HEK293 revisedConfirmatory same project related to Summary assay
2337SAR analysis of inhibitors of TNFa specific NF-kB induction revisedConfirmatory same project related to Summary assay
2466SAR analysis of compounds that inhibit NOD1 - Set 2Confirmatory same project related to Summary assay
2469SAR analysis of compounds that are cytotoxic to HEK293 - Set 2Confirmatory same project related to Summary assay
2475SAR analysis of compounds that inhibit NOD2 - Set 2Confirmatory same project related to Summary assay
2483SAR analysis of inhibitors of TNFa specific NF-kB induction - Set 2Confirmatory same project related to Summary assay
2485HTS dose response assay for identification of inhibitors of TNFa-specific NF-kB inductionConfirmatory same project related to Summary assay
2504SAR analysis of Tumor necrosis factor alpha (TNF-alpha) induced IL-8 secretion in MCF-7/NOD1 cells - Set 2Confirmatory same project related to Summary assay
2505SAR analysis of GM-Tri-DAP induced IL-8 secretion in MCF-7/NOD1 cells - Set 2Confirmatory same project related to Summary assay
2789SAR analysis of NF-kappaB dependent luciferase using Doxorucibin as an inducer - Set 2Confirmatory same project related to Summary assay
2792SAR analysis of NF-kappaB dependent luciferase using PMA/Ionomycin as an inducer - 2Confirmatory same project related to Summary assay
2793SAR analysis of NF-kappaB dependent luciferase using DAP as an inducer - Set 2Confirmatory same project related to Summary assay
2798SAR analysis of compounds that inhibit NOD1 - Set 3Confirmatory same project related to Summary assay
2799SAR analysis of compounds that inhibit NOD2 - Set 3Confirmatory same project related to Summary assay
2800SAR analysis of compounds that are cytotoxic to HEK293 - Set 3Confirmatory same project related to Summary assay
2801SAR analysis of inhibitors of TNFa specific NF-kB induction - Set 3Confirmatory same project related to Summary assay
2264SAR analysis of NF-kB dependent luciferase using DAP as an inducerConfirmatory same project related to Summary assay
2334SAR analysis of compounds that inhibit NOD2 revisedConfirmatory same project related to Summary assay
2335SAR analysis of compounds that are cytotoxic to HEK293 revisedConfirmatory same project related to Summary assay
2337SAR analysis of inhibitors of TNFa specific NF-kB induction revisedConfirmatory same project related to Summary assay
2475SAR analysis of compounds that inhibit NOD2 - Set 2Confirmatory same project related to Summary assay
2485HTS dose response assay for identification of inhibitors of TNFa-specific NF-kB inductionConfirmatory same project related to Summary assay
2793SAR analysis of NF-kappaB dependent luciferase using DAP as an inducer - Set 2Confirmatory same project related to Summary assay
2799SAR analysis of compounds that inhibit NOD2 - Set 3Confirmatory same project related to Summary assay
Description:
Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)
Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)
Network: NIH Molecular Libraries Screening Centers Network (MLSCN)
Grant Number: 1 R03 MH084844-01
Assay Provider: Dr. John C. Reed, Sanford-Burnham Medical Research Institute

The modulation of immune response activity is one of the major goals in the development of novel therapeutics for auto-immune and inflammatory diseases. The innate system resides at the intersection of the pathways of microbial recognition, inflammation, and cell death, thereby offering various therapeutic targets. In this context, NOD1 and NOD2 are of particular interest, since they recognize distinct structures derived from bacterial peptidoglycans and directly activate NF-kB, a central regulator of immune response, inflammation, and apoptosis.
The NOD proteins participate in the signaling events triggered by host recognition of specific motifs (mostly, muropeptides) in bacterial peptidoglycan (PG). Upon activation, NODs induce activation of NF-kB, a central regulator of immune response, inflammation, and apoptosis. NOD2 is a general bacterial sensor that participates in the innate immunity against Gram-positive bacteria (S. pneumoniae, L. monocytogenes), Gram-negative bacteria (S. typhimurium) and mycobacteria (M. tuberculosis), while NOD1 recognizes mainly Gram-negative bacteria (E. coli, Chlamydia, H. pylori). Prior studies have shown the muramyldipeptide (MDP), a PG component, stimulates NOD2 activation in cells, while Ala-gamma Glu-diaminopimelic acid (GM-tri-DAP) stimulates NOD1, thus providing convenient, synthetic ligands for activating the proteins in intact cells.
Interleukin-8 (IL-8) is an important mediator of the immune reaction and a major chemokine involved in inflammatory responses. Recent studies have indicated that muramyl dipeptide (MDP) induction of human breast cancer epithelial cell lines MCF-7 over-expressing NOD2 combined with small doses of cycloheximide (CHX), specifically induces IL-8 production and release (da Silva Correia, 2006; da Silva Correia 2007).
MDP induced IL-8 production assay in MCF-7 cells is developed and performed to test if the primary and confirmed hits which putatively affect NOD2-mediated NF-kB pathway. Nod2 is a general sensor of peptidoglycan through the recognition of muramyl dipeptide (MDP), the minimal bioactive peptidoglycan motif common to all bacteria (Girardin,2003). Here we used MDP to promote IL-8 secretion in MCF-7 cells.

This dose response assay is developed and performed to confirm hits originally identified in "uHTS luminescence assay for the identification of compounds that inhibit NOD1" (AID 1578) and followed up in "SAR analysis of compounds that inhibit NOD1" (AID 2072) to study the structure-activity relationship on analogs of the confirmed hits. Compounds are either acquired from commercial sources or synthesized internally.

Reference
Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G, Philpott DJ, Sansonetti PJ. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem. 2003 Mar 14;278(11):8869-72.
da Silva Correia, J., Miranda, Y., Leonard, N., Hsu, J., and Ulevitch, R. J. Regulation of Nod1-mediated signaling pathways. Cell Death Differ, 14: 830-839, 2007.
da Silva Correia, J., Miranda, Y., Austin-Brown, N., Hsu, J., Mathison, J., Xiang, R., Zhou, H., Li, Q., Han, J., and Ulevitch, R. J. Nod1-dependent control of tumor growth. Proc Natl Acad Sci U S A, 103: 1840-1845, 2006.
Protocol
Protocol:
1. MCF7 cells stably overexpressing NOD2
2. MDP-LD (Invivogen)
3. IL-8 OptEIA ELISA set (BD Biosciences, San Diego, CA)
4. SpectraMax 190 spectrophotometer (Molecular Devices)
Protocol:
1. Compounds were diluted in DMEM 10% FBS plus Pen/Strep (culture medium), and 10 uL were added into respective wells (96-well culture plate) to reach desired final concentrations.
2. MDP was added, in a final concentration of 5.4 ug/ml, to a culture medium suspension of MCF-7 cells (3,6x10+5 cells per mililiter).
3. Pre-induced MCF-7 cells were added into the respective wells (140 ul per well) and kept at 37oC (5% CO2 incubator) for 24 hours.
4. Thirty microliters of culture medium was used to measure IL-8 production using an IL-8 ELISA kit from BD according to the manufacturer's protocol. Briefly, 96-well ELISA plates (BD Biosciences) were coated with 100 uL per well of Capture Antibody diluted in Coating Buffer (100 mM Sodium carbonate, pH9.5) for overnight at 4oC. The wells were washed 3 times with 200 uL Washing Buffer (PBS with 0.05% Tween-20) and then blocked by 200 uL Assay Diluent (PBS with 10 % FBS) at room temperature for 1 h. The wells were then washed 3 times and 30 uL sample and proper amount of standards were added. The plate was sealed and incubated at 4oC overnight. After 5 total washes, 100 uL of Working Detector (detection antibody + SAv-HRP reagent) was added. The plate was then sealed and incubated for 1 h. After 7 total washes, 100 uL Substrate Solution was added and the plate was incubated for 30 min at room temperature in the dark. 50 uL Stop Solution was added and absorbance was read at 450 nm within 30 minutes on a spectrometer SpectraMax 190 (Molecular Devices). Absorbance at 570nm was subtracted from those of 450nm and data was analyzed.
5. Absorbance values were converted to IL-8 amounts (measured as pg/ml) according to standard curve analysis.
Comment
Compounds were tested in the range 0-25 uM
Compounds are considered active if they resolve to an IC50 and IC50_Mean < 25 uM.
To simplify the distinction between the inactives of the primary screen and of the confirmatory screening stage, the Tiered Activity Scoring System was developed and implemented. Its utilization for the assay is described below.
Activity Scoring
Activity scoring rules were devised to take into consideration compound efficacy, its potential interference with the assay and the screening stage that the data was obtained. Details of the Scoring System will be published elsewhere. Briefly, the outline of the scoring system utilized for the assay is as follows:
1) First tier (0-40 range) is reserved for primary screening data and is not applicable to this assay
2) Second tier (41-80 range) is reserved for dose-response confirmation data and is not applicable to this assay
3) Third tier (81-100 range) is reserved for resynthesized true positives and their analogues
a. Inactive compounds of the confirmatory stage are assigned a score value equal 81.
b. The score is linearly correlated with a compound's inhibitory potency and, in addition, provides a measure of the likelihood that the compound is not an artifact based on the available information.
c. Summary equation that takes into account the items discussed above is
Score = 82 + 3*(pIC50 - 3),
where pIC50 is a negative log(10) of the IC50 value expressed in mole/L concentration units. This equation results in the Score values above 50 for compounds that demonstrate high potency and predictable behavior. Compounds that are inactive in the assay or whose concentration-dependent behavior are likely to be an artifact of that assay will generally have lower Score values.
Categorized Comment - additional comments and annotations
From PubChem:
Assay Cell Type: MCF-7
From ChEMBL:
Assay Format: Cell-based
Assay Type: Functional
Result Definitions
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1IC50_QualifierThis qualifier is to be used with the next TID, IC50. If qualifier is "=", the IC50 result equals the value in that column. If the qualifier is ">", the IC50 result is greater than that value. If the qualifier is "<", the IC50 result is smaller than that valueString
2IC50*IC50 value determined using sigmoidal dose response equationFloatμM
3Std.Err(IC50)Standard Error of IC50 valueFloatμM
4IC50IC50 value determined using sigmoidal dose response equationFloatμM
5nHHill coefficient determined using sigmoidal dose response equationFloat

* Activity Concentration.
Additional Information
Grant Number: 1 R03 MH084844-01

Data Table (Concise)
Data Table ( Complete ):     View Active Data    View All Data
Classification
PageFrom: